[Photodynamic laser therapy with antibody-bound dyes. A new procedure in therapy of gynecologic malignancies].
In the present paper, a new therapeutic concept of photodynamic laser therapy using antibody-linked dyes for the treatment of gynecological malignancies is described. So far, HPD (hematoporphyrin derivative) has been employed in this area, but is associated with toxic systemic reactions. We see a solution to this problem in the linking of a systemically non-toxic dye--known to induce photodynamic reactions while not itself being selectively accumulated within tumor cells--to an antibody directed against a selective tumor-associated antigen. The results of our study demonstrate the efficacy of this therapeutic concept as exemplified by the selective destruction of dye-labeled ovarian carcinoma cells by laser light of a defined wavelength (675 nm). The potential of this form of photodynamic therapy extends far beyond its use in ovarian carcinoma.
Schmidt
S
S
Frauenklinik Universität, Bonn.
Wagner
U
U
Schultes
B
B
Oehr
P
P
Decleer
W
W
Ertmer
W
W
Lubaschowski
H
H
Biersack
H J
HJ
Krebs
D
D
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects*; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000473:pathology*; D010778:Photochemotherapy / Q000379:methods*; D014407:Tumor Cells, Cultured / Q000187:drug effects*; D014410:Tumor Stem Cell Assay
D000911:Antibodies, Monoclonal; D000922:Immunotoxins
Photodynamische Lasertherapie mit antikörpergebundenen Farbstoffen. Ein neues Verfahren zur Therapie gynäkologischer Malignome.